Biogen reported third quarter 2026 total revenue of $2.8 billion, up 11% from a year earlier, with the first full quarter of Apellis products contributing. GAAP diluted EPS was $(0.14) versus $3.17 a year earlier, mainly due to transaction-related charges, and non-GAAP diluted EPS fell to $2.62 from $4.81 after a $284 million acquired IPR&D, upfront and milestone expense. The company also raised the low end of its full year 2026 non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00.
Total revenue $2.8 billion, up 11% year over year; Growth Portfolio revenue $1.26 billion, up 49%
GAAP diluted EPS $(0.14) vs. $3.17 a year earlier; non-GAAP diluted EPS $2.62 vs. $4.81
$284 million acquired IPR&D, upfront and milestone expense, primarily related to the RayThera Inc. acquisition
Full year 2026 non-GAAP diluted EPS guidance low end raised to $12.20 from $12.00; range now $12.20 to $13.00
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Biogen's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$9.89B
+2.2%
$8.79
-21.4%
13.1%
FY2024
$9.68B
-1.6%
$11.18
+40.3%
16.9%
FY2023
$9.84B
-3.3%
$7.97
-61.8%
11.8%
FY2022
$10.17B
-7.4%
$20.87
+100.7%
29.9%
FY2021
$10.98B
-18.3%
$10.40
-58.1%
14.2%
Frequently asked questions
When is Biogen's next earnings date?
Biogen has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Biogen earn last quarter?
For the quarter ended Sep 2026, Biogen reported diluted EPS of $-0.14 (-104.4% year over year) on revenue of $2.80B (+10.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.